Jade Biosciences is developing therapies aimed at redefining the standard of care for autoimmune diseases. The company launched in July 2024 and its portfolio was engineered by Paragon Therapeutics. Jade has appointed Tom Frohlich as CEO and Hetal Kocinsky, M.D., as CMO to lead clinical and commercial strategy. The company also formed a Board of Directors led by Eric Dobmeier that includes industry veterans across science and business. Jade announced an expanded financing to accelerate clinical development and strengthen its balance sheet. The company is associated with Vancouver, BC and San Francisco. Jade Biosciences is developing transformative, potentially best-in-class therapies for inflammation and immunology indications, with a focus on autoimmune diseases. Its programs are preclinical and built from assets engineered by Paragon Therapeutics. The company plans to advance targeted therapies for indications with high unmet need using newly raised capital. Jade named Andrew King, D.V.M., Ph.D., as Chief Scientific Officer; he brings over 15 years of leadership across biotech and pharma and experience in discovery, nonclinical development, translational medicine, and clinical development strategy. Jade is the fourth company launched from Paragon’s assets and is headquartered in Waltham, MA.

Total raised

$175M

Funding rounds

2

Latest round

Equity

Latest activity

Oct 2024